The extended-format version of the CJC-1295 + Ipamorelin combination vial. Same synergistic GH-releasing mechanism — GHRH analogue paired with a selective GHRP — in double the volume for longer cycles or higher frequency dosing.
Identical mechanism to the 5mg format: CJC-1295 activates GHRH receptors in the pituitary; ipamorelin activates the ghrelin receptor. The dual-pathway GH stimulation produces a physiological pulsatile release without elevating cortisol, prolactin, or ACTH. The 10mg vial is suited to users who dose twice daily, run extended 12–16 week cycles, or want fewer reconstitutions across a protocol.
Growth hormone and IGF-1 rise in a pulsatile pattern. Lean mass increases, fat mobilises, sleep architecture improves, and recovery accelerates. The larger vial format reduces the number of reconstitutions required across a full cycle.
GH-driven anabolism + BPC-157 tissue repair creates a powerful recovery stack
Adds GHRH stimulation — use under guidance as GH elevation compounds
Systemic tissue healing amplifies the recovery benefits of GH secretagogue protocols
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.